James DArecca
CIK 1583903 · EVP, Chief Financial Officer · last filed 2026-08-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.37M
Companies
5
Total Filings
42
Lifetime Open-Market Net
-$81.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PBH | Director | 9,572 | $54.85 | $525.0K | $0 | 4 | 2026-08-05 |
| HAE | EVP, Chief Financial Officer | 54,444 | $87.84 | $4.78M | $0 | 13 | 2026-05-19 |
| TXMD | Chief Financial Officer | 4,343 | $2.07 | $9.0K | -$81.2K | 4 | 2021-08-12 |
| Allergan plc (AGN) Delisted | SVP Chief Accounting Officer | 0 | — | — | $0 | 18 | 2020-05-11 |
| ACT | CHIEF ACCOUNTING OFFICER | 1,182 | $48.96 | $57.9K | $0 | 2 | 2015-03-09 |
Recent Filings · Page 4 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-09 | Allergan plc (AGN) Delisted | Tax (F) | −79 | -$12.1K | EDGAR |
| 2018-03-08 | Allergan plc (AGN) Delisted | Mixed | +1,603 | $245.6K | EDGAR |
| 2018-03-06 | Allergan plc (AGN) Delisted | Tax (F) | −146 | -$21.4K | EDGAR |
| 2018-01-02 | Allergan plc (AGN) Delisted | Tax (F) | −100 | -$16.4K | EDGAR |
| 2017-10-30 | Allergan plc (AGN) Delisted | Exer (M) | +799 | $0 | EDGAR |
| 2017-03-09 | Allergan plc (AGN) Delisted | Mixed | +1,008 | $241.5K | EDGAR |
| 2017-03-07 | Allergan plc (AGN) Delisted | Tax (F) | −138 | -$33.9K | EDGAR |
| 2017-02-03 | Allergan plc (AGN) Delisted | Mixed | +146 | $33.5K | EDGAR |
| 2016-05-12 | Allergan plc (AGN) Delisted | Grant (A) | +914 | $260.0K | EDGAR |
| 2015-03-09 | ACT | Mixed | +378 | -$23.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.